C12N 2760/20171
Demonstrated in vivo effect
C12N2760/20171 (Demonstrated in vivo effect) appears on 19 US grants and 32 published applications in this corpus.
Search patents in C12N- Granted patents
- 19
- Published applications
- 32
- Assignees
- 14
- Inventors
- 42
- Latest grant
- 14 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 0 | 2 |
| 2016 | 1 | 0 |
| 2017 | 1 | 3 |
| 2018 | 0 | 4 |
| 2019 | 4 | 3 |
| 2020 | 2 | 3 |
| 2021 | 4 | 2 |
| 2022 | 2 | 4 |
| 2023 | 4 | 6 |
| 2024 | 0 | 0 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Artificial nucleic acid molecules for improved protein expression14 Oct 2025US 12,442,005 B2CureVac AG
- Artificial nucleic acid molecules for improved protein expression19 Sep 2023US 11,761,009 B2CureVac AG
- Compositions and methods for the prevention and treatment of rabies virus infection22 Aug 2023US 11,730,804 B1Replicate Bioscience, Inc.
- Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen4 Jul 2023US 11,690,910 B2CureVac AG
- Parainfluenza virus 5 based vaccines3 Jan 2023US 11,542,527 B2University of Georgia Research Foundation, Inc.
- Artificial nucleic acid molecules for improved protein expression12 Mar 2026US 2026/0071224 A1CureVac AG
- Compositions and methods for the prevention and treatment of rabies virus infection12 Jun 2025US 2025/0186574 A1Replicate Bioscience, Inc.
- Rabies g protein and uses thereof5 Jun 2025US 2025/0177513 A1Icosavax, Inc.
- Gene shuffled lyssavirus vaccine14 Dec 2023US 2023/0398201 A1Thomas Jefferson University
- Artificial nucleic acid molecules for improved protein expression5 Oct 2023US 2023/0313207 A1CureVac AG
Most cited
By later US patents
- Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant33US 11,110,166 B2CureVac AG · 2021
- Artificial nucleic acid molecules for improved protein expression32US 11,149,278 B2CureVac AG · 2021
- Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant31US 10,369,216 B2CureVac AG · 2019
- Artificial nucleic acid molecules for improved protein expression23US 11,286,492 B2CureVac AG · 2022
- Artificial nucleic acid molecules for improved protein expression17US 11,345,920 B2CureVac AG · 2022